. Author manuscript; available in PMC: 2009 Oct 17.

Published in final edited form as: Int J Radiat Oncol Biol Phys. 2008 Jan 22;71(2):338–345. doi: 10.1016/j.ijrobp.2007.10.019

Table 1.

Patient characteristics for the study group

	IMRT	¹²⁵I	p^*
n	216	158
Median age (y)	67.6 (26.7–80.6)	64.7 (42.0–78.3)	0.001
PSA (ng/ml)
<5	97 (44.9)	71 (44.9)	0.38
5–8	103 (47.7)	69 (43.7)
8–10	16 (7.4)	18 (11.4)
Median	5.2 (0.4–9.6)	5.2 (0.5–9.8)
T1c	169 (78.2)	132 (83.5)	0.005
T2a	33 (15.3)	26 (16.5)
T2b	14 (6.5)	0 (0)
Gleason score 5	8 (3.7)	6 (3.8)	0.96
Gleason score 6	208 (96.3)	152 (96.2)
Median prostate size (ml)	47.8 (12.9–160) n = 199	38.1 (22–66.8) n = 158	0.001
Median baseline AUA	6.0 (0–35) n = 167	4.0 (0–17) n = 73	0.014
Diabetes	36/216 (16.7)	18/158 (11.4)	0.15
TURP before radiotherapy	17/216 (7.9)	2/158 (1.3)	0.004
Median D90 (Gy)	NA	153.6	NA

Abbreviations: IMRT = intensity-modulated radiotherapy; PSA = prostate-specific antigen; AUA = American Urologic Association symptom score; TURP = transurethral resection of the prostate; D90 = dose to 90% of the prostate; NA = not applicable.

Values expressed as median (range) or number (percent) unless noted otherwise.

p from chi-square test.